NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Three-Drug attack on tough lung cancer
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer where standard immunotherapy has stopped working. It compares a new three-drug combination (N-803, tislelizumab, and docetaxel) against the current standard single-drug treatment (docetaxel). The main goal is to se…
Matched conditions: NSCLC STAGE IV
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Tracking survival: how does this cancer drug perform in real patients?
Disease control Recruiting nowThis study follows 150 patients in Turkey with advanced lung cancer who are receiving a standard immunotherapy drug called atezolizumab as their first treatment. Researchers will track how long patients live, how well the cancer responds, and what side effects occur during routin…
Matched conditions: NSCLC STAGE IV
Sponsor: Antalya Training and Research Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Radiation 'Hammer' aims to boost cancer drug power
Disease control Recruiting nowThis study is testing if adding a precise, high-dose radiation treatment to liver tumors helps standard immunotherapy drugs work better for people with advanced lung cancer that has spread to the liver. It will compare the standard drug treatment alone to the drug treatment plus …
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Can extra immunotherapy keep advanced lung cancer at bay?
Disease control Recruiting nowThis study is testing if continuing an immunotherapy drug called cemiplimab for up to a year helps people with a specific type of advanced lung cancer live longer without their cancer getting worse. It's for patients whose cancer has spread to only a few other sites in the body a…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for vulnerable lung cancer patients excluded from other trials
Disease control Recruiting nowThis study is testing a new targeted cancer drug called repotrectinib specifically in frail or elderly patients with advanced lung cancer driven by a specific gene change (ROS1). The goal is to see if the drug is effective and tolerable for this vulnerable group, who are often le…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Could a prostate cancer treatment help fight lung cancer?
Disease control Recruiting nowThis study is testing whether combining a hormone therapy drug (leuprorelin) with an immune-boosting drug (sintilimab) can better control advanced lung cancer. Researchers want to see if the hormone therapy rejuvenates the immune system to make the immunotherapy more effective. T…
Matched conditions: NSCLC STAGE IV
Phase: NA • Sponsor: Jinzhou Medical University • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New drug duo aims to outsmart tough lung cancers
Disease control Recruiting nowThis study is testing whether adding an oral drug called pirfenidone to an existing immunotherapy (atezolizumab) can help control advanced non-small cell lung cancer that has come back or spread after initial treatments. It will involve about 25 adults to first check safety and t…
Matched conditions: NSCLC STAGE IV
Phase: PHASE1, PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New vaccine aims to keep lung cancer drugs working longer
Prevention Recruiting nowThis early-stage study is testing a new vaccine designed to prevent or delay the cancer from becoming resistant to current targeted drugs in patients with advanced ALK-positive lung cancer. The vaccine aims to train the immune system to attack the cancer. Researchers will check i…
Matched conditions: NSCLC STAGE IV
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Prevention
Last updated Mar 30, 2026 14:32 UTC